Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 2/20 | 0.51 |
| ▸ | CDK1 | P06493 | 2/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.51 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.51 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.44 |
| ▸ | FADS1 | O60427 | 6/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | YTHDF3 | Q7Z739 | 2/20 | 0.41 |
| ▸ | YTHDC1 | Q96MU7 | 2/20 | 0.41 |
| ▸ | YTHDF1 | Q9BYJ9 | 2/20 | 0.41 |
| ▸ | YTHDF2 | Q9Y5A9 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3236525 | 0.83 | CDK1 (0.66) | CCNB2CDK1CCNB1CCNB3GRM4 | |
| SCHEMBL2908586 | 0.80 | CCNB2 (0.71) | CCNB2CDK1CCNB1CCNB3GRM4 | |
| SCHEMBL20028298 | 0.79 | CCNB2 (0.46) | CCNB2CDK1CCNB1CCNB3GRM4 | |
| SCHEMBL2904694 | 0.73 | CDK1 (0.53) | CCNB2CDK1CCNB1CCNB3MAPT | |
| SCHEMBL3444404 | 0.71 | BRAF (0.49) | GRM4FADS1GAAMAPTMEN1 | |
| SCHEMBL3444401 | 0.69 | MEN1 (0.48) | CCNB2CDK1CCNB1CCNB3GRM4 | |
| SCHEMBL3717320 | 0.69 | CCNE1 (0.47) | CCNB2CDK1CCNB1CCNB3YTHDC1 | |
| SCHEMBL3714904 | 0.69 | ADORA3 (0.41) | CCNB2CDK1CCNB1CCNB3GAA | |
| SCHEMBL3001570 | 0.69 | BRAF (0.77) | BRAFCDK2 | |
| SCHEMBL3236520 | 0.68 | CDK1 (1.00) | CCNB2CDK1CCNB1CCNB3GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1348707-B1 | Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy | USTAV EX BOTAN AV CR V V I I O (CZ) | 2010-08-25 | — | — | EP | disclosed |
| US-7745450-B2 | Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy | INSTITUTE OF EXPERIMENTAL BOTANY (CZ) | 2010-06-29 | — | — | US | disclosed |
| US-20050080097-A1 | Pyrazolo[4,3-D]pyrimidines, processes for their preparation and methods for therapy | USTAV EXPERIMENTALNI BOTANIKY AV CR (INSTITUTE OF EXPERIMENTAL BOTANY ACADEMY OF | 2005-04-14 | — | — | US | disclosed |
| WO-2003082872-A1 | NOVEL PYRAZOLO[4,3-D]PYRIMIDINES, PROCESSES FOR THEIR PREPARATION AND METHODS FOR THERAPY | USTAV EXPERIMENTALNI BOTANIKY AV CR (INSTITUTE OF EXPERIMENTAL BOTANY ACADEMY OF SCIENCES OF THE CZECH REPUBLIC) (CZ) | 2003-10-09 | — | — | WO | disclosed |
| EP-1348707-A1 | Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy | Ustav Experimentalni Botaniky AV CR (Institute of Experimental Botany Academy of Sciences of the Czech Republic) (CZ) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080097-A1 | Pyrazolo[4,3-D]pyrimidines, processes for their preparation and methods for therapy | CBR3, DHFR, AKR1C3 | CCNB2 605/4885CDK1 1081/4885CCNB1 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.